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Abstract
Damage to endothelial cells contributes to acute kidney injury (AKI) by causing impaired perfusion, while the permanent loss of the capillary
network following AKI has been suggested to promote chronic kidney disease. Therefore, strategies to protect renal vasculature may impact
both short-term recovery and long-term functional preservation post-AKI. Human adipose stromal cells (hASCs) possess pro-angiogenic and
anti-inflammatory properties and therefore have been tested as a therapeutic agent to treat ischaemic conditions. This study evaluated hASC
potential to facilitate recovery from AKI with specific attention to capillary preservation and inflammation. Male Sprague Dawley rats were sub-
jected to bilateral ischaemia/reperfusion and allowed to recover for either two or seven days. At the time of reperfusion, hASCs or vehicle was
injected into the suprarenal abdominal aorta. hASC-treated rats had significantly greater survival compared to vehicle-treated rats (88.7% ver-
sus 69.3%). hASC treatment showed hastened recovery as demonstrated by lower creatinine levels at 48 hrs, while tubular damage was signifi-
cantly reduced at 48 hrs. hASC treatment resulted in a significant decrease in total T cell and Th17 cell infiltration into injured kidneys at 2 days
post-AKI, but an increase in accumulation of regulatory T cells. By day 7, hASC-treated rats showed significantly attenuated capillary rarefaction
in the cortex (15% versus 5%) and outer medulla (36% versus 18%) compared to vehicle-treated rats as well as reduced accumulation of inter-
stitial alpha-smooth muscle actin-positive myofibroblasts. These results suggest for the first time that hASCs improve recovery from I/R-
induced injury by mechanisms that contribute to decrease in inflammation and preservation of peritubular capillaries.
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Introduction
Acute kidney injury (AKI) is associated with a high mortality rate, is
the leading cause of nephrology consultation and results in costs to
the healthcare system of approximately $10 billion annually [1].
Although there are many causes of AKI, decreased renal perfusion
secondary to endothelial damage represents a leading cause con-
tributing to kidney injury and loss of renal function [2]. Mounting evi-
dence suggests that AKI can contribute to chronic kidney disease
(CKD) and enhances the risk of end-stage renal disease (ESRD) [3,
4]. The link between AKI and the development of CKD likely involves
alterations in renal structure following tissue repair that predispose
the development of interstitial fibrosis. For example, despite recovery
of serum creatinine, it has been shown that renal capillary density is
permanently reduced in rats following AKI [5, 6]. It has been sug-
gested that this capillary rarefaction exacerbates renal hypoxia and
accelerates interstitial fibrosis [7–9]. In this regard, strategies that
improve renal blood flow or preserve renal capillaries have been
shown to provide better long-term protection from CKD development
[7–9]. In parallel, it is clear that activation of immune cells in post-
ischaemic kidneys also plays an important role in the progression of
CKD following AKI [10, 11]. These observations emphasize that
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therapeutic approaches that target both endothelial and inflammatory
processes may result in better short-term structural recovery and
mitigate progression of chronic pathological conditions.
Stem cell-based approaches have been tested as potential thera-
pies in the setting of AKI, as they offer the opportunity to promote tis-
sue repair. While studies performed with bone marrow-derived
haematopoietic progenitors have proved disappointing, marrow-
derived mesenchymal stem cells (MSCs) have shown promise in the
treatment of various ischaemic insults, including AKI [12–15]. How-
ever, the vascular protective effects and potential to mitigate progres-
sion to CKD following AKI have thus far received little attention.
Adipose-derived stromal cells (ASCs) are multipotent mesenchy-
mal progenitor cells that functionally and phenotypically resemble
pericytes, with the ability to stabilize endothelial networks [16]. While
retaining many properties of marrow-derived MSCs, ASCs may be
advantageous as they are easier to isolate, highly expandable and
therefore are more feasible for translation into the clinic. It has been
well accepted that the primary mechanism of activity of systemically
infused therapeutic cells is their paracrine activity. Multiple studies
have shown that ASCs produce a variety of soluble cytokines and exo-
somes that have anti-apoptotic, angiogenic, anti-fibrotic and
immunomodulatory activities [17–21]. We and others have shown
that these cell properties allow ASCs to be used to treat multiple
pathological conditions associated with acute local ischaemia (e.g.
myocardial infarction) and inflammation [22–25]. Other investigators
have shown that ASCs may also protect against ischaemic AKI [21,
26–28], but these studies utilized mouse-derived ASCs and did not
examine effects of cells on vascular preservation. To determine
whether human ASC-based therapies may represent a potential treat-
ment for AKI, the current study was conducted using a well-estab-
lished rat model of AKI induced by I/R injury, with a particular focus
on hASC effects on renal vasculature preservation as well as lympho-
cyte activation, as these two features are known to be associated with
progression of CKD following the initial recovery from AKI.
Materials and methods
Animals and cells
Male Sprague Dawley rats (250–300 g) were purchased from Harlan
(Indianapolis, IN, USA). Rats were maintained in accordance with the
policies of the National Institutes of Health Guide for the Care and Use
of Laboratory Animals. All protocols were approved by Institutional Ani-
mal Care and Use Committee at Indiana University.
Studies involving human adipose tissue sample collection were
approved by the Indiana University School of Medicine Institutional
Review Board. Human subcutaneous adipose tissue samples obtained
from lipoaspiration procedure were processed to isolate ASCs as
described previously [29]. In brief, the fat tissue was digested in colla-
genase type I solution (Worthington Biochemical, Lakewood, NJ, USA)
under agitation for 1 hr at 37°C and centrifuged at 300 9 g for 8 min.
to separate the stromal cell fraction (pellet) from adipocytes. The pellet
was re-suspended in DMEM/F12 containing 10% FBS (Hyclone, Ther-
mofisher.com) filtered through 100 lm Nitex filters (Sefar America Inc,
Depew, NY, USA) and centrifuged at 300 9 g for 8 min. The cell pellet
was treated with red cell lysis buffer (154 mmol/l NH4Cl, 10 mmol/l
KHCO3, 0.1 mmol/l EDTA) for 10 min. The final pellet was suspended in
EGM2-MV (Cambrex, East Rutherford, NJ, USA), plated and expanded.
The cell purity and consistency in expression of previously described sur-
face markers of ASC (CD10+, CD13+, CD29+, CD73+, CD105+, CD90)
was confirmed by phase contrast microscopy and flow cytometric tech-
nique as described previously [30] and shown in Figure 1. Briefly, ASC at
passage 4 was labelled with fluorescently tagged mouse anti-human IgG
for CD10, CD13, CD29, CD31, CD34, CD45, CD73 CD90 and CD105 or
isotype control IgGs (all were purchased from BD Biosciences), ASC was
negative for the haematopoietic marker CD45 and the endothelial marker
CD31. Passage-four cells were used for in vivo experiments.
Surgical procedures and hASCs treatment
Ischaemia/reperfusion AKI or sham-control surgery was conducted as
described previously [2]. Rats were anaesthetized with intraperitoneal
injections of ketamine (100 mg/kg) with xylazine (5 mg/kg) and then
placed on a heating pad to maintain physiological temperature. Bilateral
renal ischaemia was induced by clamping both the right and left renal
pedicle for 40 min. At the time of reperfusion, either control media or
2 9 106 hASCs (in 0.5 ml of EBM-2/1%BSA) were injected into the
suprarenal aorta. Sham-operated control animals (n = 4) were subjected
to the same procedure without pedicle clamping. Animals were allowed to
recover for 2 days (cohort 1: n = 10 for both experimental groups) or
7 days (cohort 2 n = 8 vehicle; n = 13 ASCs) to evaluate the effects of
therapy on mitigation of early injury and tissue repair, respectively.
Human ASC homing
hASCs (2 9 106 hASCs in 0.5 ml of EBM-2/1%BSA) were labelled
using Celltracker CMTPX (Thermofisher.com) according to manufacture
instructions and were injected into the suprarenal aorta at the time of
reperfusion. Kidney, spleen, lung and hindlimb skeletal muscles were
harvested at 10 min. and 48 hrs post-injection, then immediately sec-
tioned without fixation and evaluated for the presence of fluorescent
cells using confocal microscopy (Olympus FV 1000-MPE microscope,
Center Valley, PA, USA).
Measurement of renal function
At the indicated times, blood was collected in heparin-treated Eppendorf
tubes and centrifuged at 3000 9 g for 10 min. Plasma creatinine was
measured using creatinine reagent kit on Point Scientific QT 180 Ana-
lyzer (Point Scientific, Inc, Canton, MI, USA) according to manufac-
turer’s specifications.
Evaluation of renal structure
At the end of the study, kidneys were harvested for histological analysis
and fluorescence-activated cell sorting analysis. Portions of the kidney
were fixed with either formalin or methanol. To evaluate the extent of
renal tubular damage, formalin-fixed paraffin-embedded sections were
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stained with haematoxylin and eosin. Six random images (three cortex,
three outer medulla) were obtained using a Leica DMLB (Scientific
Instruments, Columbus, OH, USA) microscope using a 209 objective.
For each kidney, an average of 60 tubules were scored from images by
an observer who was blinded to the treatments using a 1–4 scoring
system described previously [31]. Data presented are based on the
average score per tubule for each animal.
Evaluation of microvessel density and
myofibroblasts
Renal capillaries were stained as described previously [32]. Briefly,
methanol-fixed vibratome sections of kidneys were subjected to
immunofluorescent staining using the highly specific capillary marker,
cablin (A generous gift from Dr. Robert Bacallao) [33]. Cablin-specific
signals were developed using a tyramide signal amplification kit (Invit-
rogen, Carlsbad, CA, USA) as described previously [32]. Confocal
images were obtained using an Olympus FV 1000-MPE microscope.
Renal capillary density was determined from a minimum of 10 random
images per kidney (five cortex, five outer medulla) by counting the
number of stained structures intersecting an arbitrary grid, with the aid
of ImageJ software (National Institutes of Health), as described [32].
Data are expressed as % change in vessel density compared to the
mean value of sham-operated control rats.
In parallel, formalin-fixed paraffin-embedded kidney sections were
stained with mouse anti-rat alpha-smooth muscle actin (a-SMA) anti-
body (Invitrogen) and developed using Histomouse-SP staining kit-AEC
(Life Technologies, Carlsbad, CA, USA). Three random images from
renal outer medulla were obtained from each rat by light microscopy.
Scoring of a-SMA was quantified by overlaying an arbitrary array of
gridlines to a density of 520 boxes per visual field with the aid of
ImageJ software. The number of boxes containing a-SMA-positive
structures was counted, and data are expressed as the % of boxes with
a-SMA-positive structures per visual field.
Fluorescence-activated cell sorting
Harvested kidneys were minced and digested in TL Liberase (2 lg/ml;
Roche) for 15 min. at 37°C in gentleMACS dissociator (Miltenyli, San
Diego, CA, USA). The obtained cell suspension was filtered through a
100-lm filter mesh and washed with medium. The lymphocytes were
separated by Percoll (Sigma-Aldrich, Carlsbad, CA, USA) and counted
by haemocytometer [10]. To label T lymphocytes, the cells were stained
with anti-rat antibodies against CD4 (PE-Cy7), CD8a (Alexa 647), FOXp3
(PE) and CD25. To evaluate IL-17 secretion by T cells, the cells were
first stained for surface CD4, then permeabilized with 0.1% saponin and
stained with antibodies against rat IL-17 (FITC). Cells were scanned
using a FACS Calibur analyzer (BD Biosciences, San Jose, CA, USA)
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Fig. 1 (A) Representative phase contrast image of ASC at passage 4 when cultured in EBM-2mv media. (B) Fluorescence-activated cell sorting analyses
of ASC at passage 4. Fluorescent signals for cells with isotype IgG are shown as dotted line and antigen-specific signals are shown as grey-filled curves.
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and analysed using Flowjo software (Tree Star, Ashland, OR, USA). Gat-
ing strategies were exactly as described previously [10], and represen-
tative plots and associated gating strategies are shown in Figure S1.
Statistical analysis
Data are presented as mean  S.E.M, unless otherwise stated. Statisti-
cal analyses were performed with GraphPad Prism 5 (GraphPad Soft-
ware, La Jolla, CA, USA). ANOVA and Student’s t-test analysis were used
to assess differences between data means as appropriate. Survival was
evaluated using Log-rank (Mantel-Cox) test. A P-value of <0.05 was
used for the criterion of significance.
Results
Human ASCs significantly improves renal
function following renal I/R
To determine the effects of hASC on renal recovery following I/R
in rat model, hASCs or vehicle was injected into the suprarenal
aorta at the time of reperfusion and allowed to recover for 2 days
(cohort 1). As the importance of inflammatory component in I/R
injury is well described [10, 34–37], this study was specifically
designed with immunocompetent animals, rather than with
immunocompromised athymic nude rats or NOD/SCID mice. It has
been shown that systemic infusion of human mesenchymal cells,
including ASC, into immunocompetent rodents and larger animals
produce positive therapeutic effects [18, 22, 23, 38–40], without
evident rejection responses. As expected, in vehicle-treated rats, I/
R resulted in a significant increase in serum creatinine at 24 and
48 hrs after injury/treatment (Fig. 2A). The loss of renal function
was associated with a significant renal tubular damage with evi-
dence of cellular necrosis, cell sloughing and tubular dilatation
both in the renal cortex and renal medulla (Fig. 2B and C). When
rats were treated with hASCs, serum creatinine levels were similar
at 24 hrs post-I/R relative to vehicle, but there was a significant
diminution of its levels by 48 hrs (Fig. 2A) and the degree of
tubular damage was also diminished at 48 hrs following I/R
(Fig. 2B and C).
Previous studies that used bone marrow-derived MSC in the set-
ting of AKI have shown low frequency of homing of injected cells to
the injured kidneys [41]. To determine whether the therapeutic effect
Fig. 2 hASCs ameliorate renal injury following I/R. (A) Serum creatinine levels were measured in the rats 24 and 48 hrs post sham surgery or after
I/R injury followed by infusion of 2 9 106 hASC or vehicle. (B) Representative images of haematoxylin/eosin stained cross sections through renal
cortex and outer medulla of kidneys harvested 48 hrs post sham-operation or I/R followed by either vehicle or hASC treatment. Note the presence
of dilated tubules containing sloughed cells (black arrow) and necrotic cellular debris (white arrow) in cortex and outer medulla of vehicle-treated
kidneys, while less severe tubular damage is observed in hASC-treated kidneys. (C) Tubular injury scores derived from haematoxylin and eosin
stained sections Data presented as mean  S.E.M; *indicates P < 0.05 I/R+hASC versus I/R+vehicle by Student’s t-test.
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of human ASC depends on cell homing to the site of injury, we
labelled ASC with Celltracker-CMTPX (red fluorescent dye) and
administered them at reperfusion. Confocal microscopy analysis of
multiple cross sections of kidneys tissues, prepared immediately after
harvest, has clearly shown that injected cells were undetectable in the
kidneys neither at 10 min. nor at 48 hrs following renal I/R (Fig. S2).
In contrast, a small number of cells were found in lung (Fig. S2) and
potentially in skeletal muscles of hindlimbs (not shown), but not in
spleen.
hASCs infusion reduces infiltration of
inflammatory cells following I/R
The increased expression of IL-6 has been suggested to play an
important role in mediating lymphocyte infiltration into post-ischae-
mic kidney [42]. Here we found that while renal I/R significantly
increased renal IL-6 expression, kidneys obtained from the rats that
received ASC therapy had significantly attenuated expression of IL-6
(Fig. 3A), thus suggesting that ASC convey anti-inflammatory proper-
ties following renal injury.
Infiltrating cells including lymphocytes play a significant role in
AKI [35, 36]. When infiltrating lymphocytes were evaluated 48 hrs
post-I/R, the numbers of CD4+ and CD8+ lymphocytes and B cells
were not affected by hASC treatment relative to vehicle (Table 1).
Recently, Chan et al. and we previously demonstrated that T-helper
17 (Th17) cells are increased early following ischaemia and contribute
to the severity of AKI [10, 43]. Consistent with our prior results, I/R
injury significantly increased the total number of IL17+ expressing
cells in the injured kidney relative to sham (Fig. 3B). Interestingly,
hASC treatment protected kidneys from the accumulation of total
IL17+ cells, as well as CD4 + IL17+ and CD8 + IL17+ when com-
pared with vehicle-treated I/R rats (Table 1). hASC therapy was
accordingly associated with a decrease in the percentage of IL17 + /
CD4+ T cells (Fig. 3C), but did not influence Th1 (CD4 + IL4+) or
Th2 (CD4 + IFNc+) polarization (Table 1). It has been suggested that
T regulatory cells (Foxp3+) are associated with modulating T cell
activity following renal injury [35]. Interestingly, at 48 hrs post-I/R,
the number of CD4 + /Foxp3+ and CD8 + /Foxp3+ cells were signifi-
cantly greater in hASC-treated rats compared with vehicle (Table 1),
which increased the ratio of regulatory Foxp3+ T cells to pro-inflam-
matory IL17+ T cells (Fig. 3D). An additional study was conducted to
Fig. 3 hASCs modulate inflammatory cytokines, reduce accumulation of IL17-secreting cells and increase T regulatory cells in kidneys following I/R.
(A) RT-PCR of whole kidney RNA for IL-6 is shown for post-ischaemic versus ASC-treated rat kidneys at 48 hrs post-injury. (B-E) Kidney resident
lymphocytes were isolated from 48 hrs post-surgery/treatment and evaluated for total number of IL17+ T cells (B), % of IL17+/CD4+ T cells (C)
and the ratio of Foxp3+/IL17+ cells (D) and CD25high/Foxp3+ natural T regulatory cells (E and F) using fluorescence-activated cell sorting. Data are
expressed as mean  S.E.M.; *indicates P < 0.05 I/R vehicle vs sham; # indicates P < 0.05 I/R+hASC vs I/R vehicle.
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determine whether the increase in T regulatory cells in ASC-treated
rats was due to the presence of CD25high/Foxp3+ population corre-
sponding to natural T regulatory cells [44]. Gating strategies to iden-
tify this population are shown in Figure S1. As shown in Figure 3E,F,
ASC treatment significantly increased the number of CD25high/Fox-
p3 + CD4 or CD8 cells in 2-day post-ischaemic kidney relative to their
levels in kidneys of vehicle-treated rats. Taken together, these data
indicate that hASC therapy modulates T cell differentiation post-I/R by
reducing IL17-secreting cells and increasing the number of Foxp3+ T
regulatory cells.
hASCs improve survival and recovery following I/R
Renal I/R injury results in a permanent loss of renal capillaries, which
is detectable by 7 days post-I/R, a time-point at which improvement
in renal function is evident [5, 45]. Therefore, an additional study (co-
hort 2) was conducted by extending survival time to 7 days post-I/R.
Similar to cohort 1, serum creatinine levels were elevated at 24 and
48 hrs post-I/R and were significantly reduced in hASC-treated rats
relative to vehicle-treated rats at 48 hrs (Fig. 4B–D). hASC treatment
substantially lowered the mortality rate of rats post-I/R such that
31% of vehicle-treated rats died by day 7 post-I/R versus only 11% of
hASC-treated rats (P < 0.05) (Fig. 4A).
As is typical for this model, creatinine values return to sham-oper-
ated control levels by day 7 in surviving vehicle- and hASC-treated
rats. Because of the effect on mortality, the number of animals con-
tributing to each data point in Figure 4B is not consistent, but rather
changes over the course of the study. Because animals that were
most severely injured most likely perished during the recovery period,
data on recovery of function (creatinine level) are biased by removing
the contribution of the most severely injured rats. Therefore, we also
examined serum creatinine levels using only data from rats that sur-
vived for the entire 7-day protocol (Fig. 4C). Importantly, in surviving
rats, the rise in serum creatinine at 24 hrs and the reduction at
48 hrs by hASCs was similar to that observed within the entire cohort
(compare Fig. 4B to C).
Because ASCs have vasculogenic activities, we sought to deter-
mine whether hASCs would have beneficial effects on capillary
preservation. Despite the resolution of serum creatinine by day 7, per-
itubular capillary density measured by cablin immunofluorescence
was significantly reduced in vehicle-treated I/R rats, consistent with
previous observations [32]. This reduction in capillary density was
significantly attenuated in hASC-treated rats both in the renal cortex
(15% versus 5%) and outer medulla (36% versus 18%) (Fig. 5A–C).
hASCs inhibit myofibroblast formation following
I/R
The activity of aSMA-positive myofibroblasts is considered to rep-
resent an important mediator of renal interstitial fibrosis. Therefore,
we also evaluated the effect of hASC on myofibroblast content
7 days following I/R. As expected, vehicle-treated rats demon-
strated elevated myofibroblast staining compared to sham-operated
controls (Fig. 6A/B), while hASC-treated rats showed a dramatic
reduction in myofibroblast staining relative to vehicle-treated rats
(Fig. 6C/D).
Table 1 Effect of hASCs on infiltration of cells following I/R. Shown are the number of different infiltrating cell types expressed per gram
kidney weight 48 hrs following I/R. Data are expressed as mean  S.E.M.
Treatment
Sham I/R+ Vehicle I/R+ hAsc
CD4+ 6441  100 8769  1943 9420  945
CD8+ 7339  756 19675  5062 20055  2761
B cells 13886  620 10067  1680 10403  1438
DC/Macs 11030  771 8603  1176 9523  1993
CD4 + IL-4+ (Th1) 248  22 251  79 253  44
CD4 + IFN-c+ (Th2) 408  33 461  60 408  117
Total IL-17+ 13416  5691 35697  5600† 12509  1446*
CD4 + IL-17+ 2573  203 3615  1000 1043  281*
CD8 + IL-17+ 2082  826 4146  875 1722  416*
CD4 + Foxp3+ 852  627 632  148 1038  159*
CD8 + Foxp3+ 55  12 137  62 282  81*
*indicates P < 0.05 I/R+hASC versus I/R+vehicle. †indicates P < 0.05 in I/R+ vehicle versus sham by ANOVA.
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Discussion
Acute kidney injury remains a significant problem in the clinical
setting. Despite advances in renal replacement therapies, mortality
rates have remained at high levels for decades, with no improve-
ment [1, 46]. Moreover, surviving patients are predisposed to
develop CKD [45]. There is therefore a pressing need for novel
therapies to promote renal cellular repair and improve tissue
remodelling. Over the past decade, advances in the field of regen-
erative medicine allowed the development of cell-based therapies
that can potentially benefit kidney repair. Previous studies have
found that bone marrow-derived MSCs have reno-protective effects
and enhance tissue regeneration after AKI in rodents [12, 13, 26,
47–50], suggesting that such cell therapy holds potential as an
option to treat patients with AKI. ASCs, which share many proper-
ties of bone marrow MSCs and are as potent in multiple regenera-
tive applications, have gained significant interest as a clinically
feasible therapeutic option. ASCs, which are abundant in the adult
human body, are known to produce a variety of angiogenic, pro-
survival and immunomodulatory factors [51]. It has been demon-
strated that ASCs, through both paracrine and direct physical
interaction with endothelial cells, modulate angiogenesis and vas-
cular stability [19, 29, 52].
Primary characteristics of renal I/R injury are the increase in
serum creatinine and damage to the tubular epithelium [2]. Bi et al.
demonstrated that mouse ASCs diminished renal tubular apoptosis,
preserved renal function and improved survival in cisplatin-induced
AKI [26]. Recently, Katsuno et al. demonstrated the potential efficacy
of hASC to ameliorate injury in a folate model of AKI in rats [53]. The
current study extends these observations by demonstrating the
potential for human ASCs to ameliorate renal tubular damage and
limit both inflammation and subsequent deterioration of the
microvasculature following I/R injury. The reduction in serum crea-
tinine was not immediate (24 hrs post-I/R) but evident by 48 hrs,
similar to previous observations using MSCs [13]. However, in con-
trast to other studies using MSCs which did not show a significant
effect on mortality [13], our current study using ASCs showed a sig-
nificant reduction in mortality in this model of AKI. The exact mecha-
nisms by which hASCs convey protection and reduce renal injury is
unclear and likely multifactorial. Several parallel studies have failed to
demonstrate MSC retention [26, 29, 53] after infusion, whereas other
studies conducted with MSCs and ASCs suggested that the primary
Fig. 4 hASCs increase survival and enhance recovery following renal I/R. (A) Survival graph of post-ischaemic rats treated with vehicle or hASCs.
(* indicates P < 0.05 I/R+hASC versus I/R+vehicle by Mantel-Cox test). (B) Serum creatinine values for sham-operated, I/R+vehicle and I/R+hASCs
are shown for all rats. Because of rat mortality over the course of the study, the ‘n’ for each treatment group is indicated in parentheses for each
time-point. (C) Serum creatinine values plotted only for rats that survived for the entire length of seven-day experiment (rats that died during the
experiment were excluded in this analysis). (D) Graph represents change in serum creatinine level between 24 and 48 hrs after injury/treatment.
Data presented as mean  S.E.M; *indicates P < 0.05 I/R+hASC versus I/R+vehicle by Student’s t-test.
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therapeutic effects are due to secreted factors. In support of prior
studies, our analysis of multiple section of the kidneys has clearly
shown minimal, if any, homing and retention of Celltracker-CMTPX-
labelled hASCs in the treated kidneys. This supports the hypothesis
that therapeutic effects of ASC are mediated by paracrine activity at a
distance [54]. Further studies will be conducted to specifically assess
the reno- and vascular protective effects of concentrated media con-
ditioned by ASC.
Inflammatory cell infiltration plays a prominent role in the evolu-
tion of AKI, primarily in the outer medulla [2]. Following I/R, the
injured renal parenchymal cells and endothelial cells facilitate traffick-
ing of innate lymphoid cells into the kidney [55]. T cells, depending
upon the activating signals, can differentiate into several effector T-
helper subsets. Recently, it has been suggested that Th17 cells play a
role in kidney injury, as IL17A-deficient mice, manifest reduced injury
in a model of cisplatin-induced AKI [43]. We have previously shown
that Th17 cells play an important role in AKI and subsequent progres-
sion to CKD [10]. Multiple studies suggest that MSCs modulate Th17
polarization in vitro [56, 57]. Furthermore, in an experimental autoim-
mune encephalomyelitis (EAE) mouse model, treatment with MSCs
reduced Th1 and Th17 differentiation and increased T regulatory cells
[58]. In parallel with these results, the current study indicates for the
first time that hASCs do not influence the accumulation of CD4+ and
CD8+ T cells in the kidney, but rather inhibit their polarization into a
pro-inflammatory (Th17+) phenotype [53] (Table 1). hASCs further
modulate the inflammatory response by increasing T regulatory (Fox-
p3+) cells in kidney parenchyma.
A common feature present in all models of kidney disease is the
reduction in peritubular capillary density, which is thought to fuel
hypoxia and accelerate the development of interstitial fibrosis [5, 59].
The exacerbation of renal hypoxia is known to stimulate the produc-
tion of pro-fibrotic factors such as TGF-b and extracellular matrix
molecules such as collagen and fibronectin, further expanding the
interstitial compartment and leading to a decrease in the efficiency of
oxygen delivery to the tubules, creating a vicious cycle for progres-
sive renal disease [5]. Thus, loss of peritubular capillaries and the
generation of renal interstitial cells that produce extracellular matrix
are of central interest in understanding the development of renal
fibrosis. With regard to the loss of endothelial cells, we have demon-
strated that endothelial to mesenchymal cell transition (EndoMT)
plays an important role contributing to capillary rarefaction [32]. This
activity can be reversed by the exogenous administration of VEGF-
121 [32]. It has also been suggested that pericyte activation, in the
setting of renal ischaemia, results from a loss of contact with injured
peritubular capillary endothelial cells. Elegant studies have demon-
strated that injury-activated pericytes lose their ability to stabilize
Fig. 5 hASCs preserve renal capillary density following I/R. (A) Representative images of cablin-stained cross sections of kidneys harvested 7 days
following I/R injury/treatment or sham surgery. Confocal derived micrographs are shown for renal cortex or renal outer medulla. Cablin-stained kid-
ney sections were scored for vessel density using ImageJ and are shown for renal cortex (B) and outer medulla (C). Data are normalized to, and
expressed as per cent of sham-operated controls (mean  S.E.M). *indicates P < 0.05 I/R+hASC versus I/R+vehicle; #indicates P < 0.05 in I/R+
vehicle versus sham by ANOVA.
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capillary endothelial cells and are a primary source of interstitial
myofibroblasts contributing to renal fibrosis [60–62]. In the current
study, hASCs, which are known to have pro-angiogenic properties,
were shown to preserve capillaries and attenuate myofibroblast devel-
opment following I/R, features thought to be critical for the progression
of CKD. We have shown that ASC secrete multiple endothelial survival
factors, including VEGF and HGF as well as SDF-1, the factors respon-
sible for attaching circulating bone marrow-derived progenitor cells to
the site of injury [17, 63, 64]. Whether the primary targets of ASC ther-
apy are endothelial cells, pericytes or lymphocytes, or whether ASC
provide their effects through several parallel mechanisms in regard to
the development of interstitial fibrosis is not yet clear.
In summary, we have demonstrated that hASCs convey vascular
protection, decrease inflammation and incite significant repair follow-
ing AKI in immunocompetent rats. Recently, potentially promising
studies from a phase 1 clinical trial indicated the potential benefit of
bone marrow-derived MSCs on deterioration of renal function, hospi-
tal length of stay and need for readmission in a population of coro-
nary artery bypass patients susceptible to AKI [65]. However, these
studies were not focused on long-term renal functional end-points,
and no further follow-up trials have been published. Given that AKI is
associated with CKD development, a growing challenge in patient care
will be developing therapeutic strategies to minimize progression fol-
lowing AKI. In addition to improving acute effects and survival, our
data suggest a potential long-term benefit as the primary mediators
of CKD, that is vascular rarefaction, myofibroblast formation and
inflammation, are attenuated with hASC treatment. Given the
increased momentum of ASCs in clinical trials, we propose that these
cells may be useful for clinical application in AKI with end-points
focused on both recovery and attenuation of CKD.
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Figure S1 Gating strategies for the phenotypic analysis of infiltrating
CD4+ T cells in the kidney. Lymphocytes were gated based on the
forward scatter versus side scatter, which is further gated on CD4+/
CD8+ T cells. Right column: These T cells were analyzed further
based on the activation markers for IL-17 (shown as histogram) or
IL4 and IFNc (shown as dot plot). For T-regulatory cells, the
population of T-regulatory cells was defined as Foxp3+/CD25high
using contour plot analysis as shown in the lower right panel.
Figure S2 hASC fail to home to the kidney following ischemia reperfu-
sion injury. Shown are representative confocal images of Celltracker-
CMTPX labeled ASCs in vitro just prior to injection (A) and in kidney
(B and D) or lung (C and E) at 10 min. (B and C) or 48 hrs (D and E)
following administration. No cells were detected in kidney at any time,
while cells were occasionally observed in lung. Representative of 3
animals per time point.
References
1. Rewa O, Bagshaw SM. Acute kidney
injury-epidemiology, outcomes and eco-
nomics. Nat Rev Nephrol. 2014; 10: 193–
207.
2. Basile DP, Anderson MD, Sutton TA. Patho-
physiology of acute kidney injury. Compr
Physiol. 2012; 2: 1303–53.
3. Basile DP, Bonventre JV, Mehta R, et al.
Progression after AKI: understanding mal-
adaptive repair processes to predict and
identify therapeutic treatments. J Am Soc
Nephrol. 2016; 27: 687–97.
4. Chawla LS, Eggers PW, Star RA, et al.
Acute kidney injury and chronic kidney dis-
ease as interconnected syndromes. N Engl J
Med. 2014; 371: 58–66.
5. Basile DP. Rarefaction of peritubular capil-
laries following ischemic acute renal failure:
a potential factor predisposing to progres-
sive nephropathy. Curr Opin Nephrol Hyper-
tens. 2004; 13: 1–7.
6. Basile DP, Donohoe D, Roethe K, et al.
Renal ischemic injury results in permanent
damage to peritubular capillaries and influ-
ences long-term function. Am J Physiol
Renal Physiol. 2001; 281: F887–99.
7. Leonard EC, Friedrich JL, Basile DP. VEGF-
121 preserves renal microvessel structure
and ameliorates secondary renal disease fol-
lowing acute kidney injury. Am J Physiol
Renal Physiol. 2008; 295: F1648–57.
8. Tome LA, Yu L, de Castro I, et al. Beneficial
and harmful effects of L-arginine on renal
ischaemia. Nephrol Dial Transplant. 1999;
14: 1139–45.
9. Basile DP, Donohoe DL, Roethe K, et al.
Chronic renal hypoxia after acute ischemic
injury: effects of l-arginine on hypoxia and
secondary damage. Am J Physiol Renal
Physiol. 2003; 284: F338–48.
10. Mehrotra P, Patel JB, Ivancic CM, et al. Th-
17 cell activation in response to high salt fol-
lowing acute kidney injury is associated with
progressive fibrosis and attenuated by AT-1R
antagonism. Kidney Int. 2015; 88: 776–84.
11. Pechman KR, Basile DP, Lund H, et al.
Immune suppression blocks sodium-sensi-
tive hypertension following recovery from
ischemic acute renal failure. Am J Physiol
Regul Integr Comp Physiol. 2008; 294:
R1234–9.
12. Togel FE, Westenfelder C. Kidney protection
and regeneration following acute injury: pro-
gress through stem cell therapy. Am J Kid-
ney Dis. 2012; 60: 1012–22.
13. Togel F, Cohen A, Zhang P, et al. Autolo-
gous and allogeneic marrow stromal cells
are safe and effective for the treatment of
acute kidney injury. Stem Cells Dev. 2009;
18: 475–85.
14. Togel F, Westenfelder C. The role of multipo-
tent marrow stromal cells (MSCs) in tissue
regeneration. Organogenesis. 2011; 7: 96–100.
15. Zander AR, Lange C, Westenfelder C. Mes-
enchymal stromal cells: main factor or
helper in regenerative medicine? Kidney Int
Suppl. 2011; 1: 74–6.
16. Grimes BR, Steiner CM, Merfeld-Clauss S,
et al. Interphase FISH demonstrates that
human adipose stromal cells maintain a
high level of genomic stability in long-term cul-
ture. Stem Cells Dev. 2009; 18: 717–24.
17. Merfeld-Clauss S, Lupov IP, Lu H, et al.
Adipose stromal cells differentiate along a
smooth muscle lineage pathway upon
endothelial cell contact via induction of acti-
vin A. Circ Res. 2014; 115: 800–9.
18. Traktuev DO, March KL, Tkachuk VA, et al.
Adipose tissue stromal cells – multipotent
cells with therapeutic potential for
stimulation of angiogenesis in tissue ische-
mia. Kardiologiia. 2006; 46: 53–63.
19. Traktuev DO, Merfeld-Clauss S, Li J, et al.
A population of multipotent CD34-positive
adipose stromal cells share pericyte and
mesenchymal surface markers, reside in a
periendothelial location, and stabilize
endothelial networks. Circ Res. 2008; 102:
77–85.
20. Zhao Q, Ren H, Han Z. Mesenchymal stem
cells: Immunomodulatory capability and
clinical potential in immune diseases. J Cell
Immunother. 2016; 2: 3–20.
21. Shih YC, Lee PY, Cheng H, et al. Adipose-
derived stem cells exhibit antioxidative and
antiapoptotic properties to rescue ischemic
acute kidney injury in rats. Plast Reconstr
Surg. 2013; 132: 940e–51e.
22. Hong SJ, Traktuev DO, March KL. Therapeu-
tic potential of adipose-derived stem cells in
vascular growth and tissue repair. Curr Opin
Organ Transplant. 2010; 15: 86–91.
23. Kono TM, Sims EK, Moss DR, et al. Human
adipose-derived stromal/stem cells protect
against STZ-induced hyperglycemia: analy-
sis of hASC-derived paracrine effectors.
Stem Cells. 2014; 32: 1831–42.
24. Hadad I, Johnstone BH, Brabham JG, et al.
Development of a porcine delayed wound-
healing model and its use in testing a novel
cell-based therapy. Int J Radiat Oncol Biol
Phys. 2010; 78: 888–96.
25. Rajashekhar G, Ramadan A, Abburi C,
et al. Regenerative therapeutic potential of
adipose stromal cells in early stage diabetic
retinopathy. PLoS One. 2014; 9: e84671.
26. Bi B, Schmitt R, Israilova M, et al. Stromal
cells protect against acute tubular injury via
an endocrine effect. J Am Soc Nephrol.
2007; 18: 2486–96.
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1429
J. Cell. Mol. Med. Vol 21, No 7, 2017
27. Yao W, Hu Q, Ma Y, et al. Human adipose-
derived mesenchymal stem cells repair cis-
platin-induced acute kidney injury through
antiapoptotic pathways. Exp Ther Med.
2015; 10: 468–76.
28. Burgos-Silva M, Semedo-Kuriki P, Doni-
zetti-Oliveira C, et al. Adipose tissue-
derived stem cells reduce acute and chronic
kidney damage in mice. PLoS One. 2015;
10: e0142183.
29. Rajashekhar G, Traktuev DO, Roell WC,
et al. IFATS collection: adipose stromal cell
differentiation is reduced by endothelial cell
contact and paracrine communication: role
of canonical Wnt signaling. Stem Cells.
2008; 26: 2674–81.
30. Bourin P, Bunnell BA, Casteilla L, et al.
Stromal cells from the adipose tissue-
derived stromal vascular fraction and culture
expanded adipose tissue-derived stromal/
stem cells: a joint statement of the Interna-
tional Federation for Adipose Therapeutics
and Science (IFATS) and the International
Society for Cellular Therapy (ISCT).
Cytotherapy. 2013; 15: 641–8.
31. Corridon PR, Rhodes GJ, Leonard EC,
et al. A method to facilitate and monitor
expression of exogenous genes in the rat
kidney using plasmid and viral vectors.
Am J Physiol Renal Physiol. 2013; 304:
F1217–29.
32. Basile DP, Friedrich JL, Spahic J, et al.
Impaired endothelial proliferation and
mesenchymal transition contribute to vas-
cular rarefaction following acute kidney
injury. Am J Physiol Renal Physiol. 2011;
300: F721–33. 12/01. 09/15/received. 11/
28/accepted.
33. Charron AJ, Xu W, Bacallao RL, et al.
Cablin: a novel protein of the capillary basal
lamina. Am J Physiol. 1999; 277: H1985–96.
34. Rabb H, Griffin MD, McKay DB, et al.
Inflammation in AKI: current understanding,
key questions, and knowledge gaps. J Am
Soc Nephrol. 2016; 27: 371–9.
35. Rabb H, O’Meara YM, Maderna P, et al.
Leukocytes, cell adhesion molecules and
ischemic acute renal failure. Kidney Int.
1997; 51: 1463–8.
36. Kinsey GR, Okusa MD. Expanding role of T
cells in acute kidney injury. Curr Opin
Nephrol Hypertens. 2014; 23: 9–16.
37. Akcay A, Nguyen Q, Edelstein CL. Mediators
of inflammation in acute kidney injury. Medi-
ators Inflamm. 2009; 2009: 137072.
38. Grinnemo KH, Mansson A, Dellgren G, et al.
Xenoreactivity and engraftment of human
mesenchymal stem cells transplanted into
infarcted rat myocardium. J Thorac Cardio-
vasc Surg. 2004; 127: 1293–300.
39. Villanueva S, Carreno JE, Salazar L, et al.
Human mesenchymal stem cells derived
from adipose tissue reduce functional and
tissue damage in a rat model of chronic
renal failure. Clin Sci (Lond). 2013; 125:
199–210.
40. Morigi M, Introna M, Imberti B, et al.
Human bone marrow mesenchymal stem
cells accelerate recovery of acute renal injury
and prolong survival in mice. Stem Cells.
2008; 26: 2075–82.
41. Togel F, Weiss K, Yang Y, et al. Vascu-
lotropic, paracrine actions of infused mes-
enchymal stem cells are important to the
recovery from acute kidney injury. Am J
Physiol Renal Physiol. 2007; 292: F1626–35.
42. Nechemia-Arbely Y, Barkan D, Pizov G,
et al. IL-6/IL-6R axis plays a critical role in
acute kidney injury. J Am Soc Nephrol.
2008; 19: 1106–15.
43. Chan AJ, Alikhan MA, Odobasic D, et al.
Innate IL-17A–producing leukocytes pro-
mote acute kidney injury via inflammasome
and toll-like receptor activation. Am J Pathol.
2014; 184: 1411–8.
44. Hsieh C-S, Lee H-M, Lio C-WJ. Selection of
regulatory T cells in the thymus. Nat Rev
Immunol. 2012; 12: 157–67.
45. Basile DP, Bonventre JV, Mehta R, et al.
Progression after AKI: understanding mal-
adaptive repair processes to predict and
identify therapeutic treatments. J Am Soc
Nephrol. 2016; 27: 687–97.
46. Chertow GM, Burdick E, Honour M, et al.
Acute kidney injury, mortality, length of stay,
and costs in hospitalized patients. J Am Soc
Nephrol. 2005; 16: 3365–70.
47. Togel F, Zhang P, Hu Z, et al. VEGF is a
mediator of the renoprotective effects of mul-
tipotent marrow stromal cells in acute kidney
injury. J Cell Mol Med. 2009; 13: 2109–14.
48. Togel FE, Westenfelder C. Mesenchymal
stem cells: a new therapeutic tool for AKI.
Nat Rev Nephrol. 2010; 6: 179–83.
49. Rabb H. Paracrine and differentiation mech-
anisms underlying stem cell therapy for the
damaged kidney. Am J Physiol Renal Phys-
iol. 2005; 289: F29–30.
50. Lange C, Schroeder J, Stute N, et al. High-
potential human mesenchymal stem cells.
Stem Cells Dev. 2005; 14: 70–80.
51. Rehman J, Traktuev D, Li J, et al. Secretion
of angiogenic and antiapoptotic factors by
human adipose stromal cells. Circulation.
2004; 109: 1292–8.
52. Traktuev DO, Prater DN, Merfeld-Clauss S,
et al. Robust functional vascular network
formation in vivo by cooperation of adipose
progenitor and endothelial cells. Circ Res.
2009; 104: 1410–20.
53. Katsuno T, Ozaki T, Saka Y, et al. Low
serum cultured adipose tissue-derived stro-
mal cells ameliorate acute kidney injury in
rats. Cell Transplant. 2013; 22: 287–97.
54. Xie J, Broxmeyer HE, Feng D, et al. Human
adipose-derived stem cells ameliorate cigar-
ette smoke-induced murine myelosuppres-
sion via secretion of TSG-6. Stem Cells.
2015; 33: 468–78.
55. Kelley VR. Leukocyte-renal epithelial cell
interactions regulate lupus nephritis. Semin
Nephrol. 2007; 27: 59–68.
56. Ghannam S, Pene J, Torcy-Moquet G, et al.
Mesenchymal stem cells inhibit human Th17
Cell differentiation and function and induce a
T regulatory cell phenotype. J Immunol.
2010; 185: 302–12.
57. Luz-Crawford P, Noel D, Fernandez X, et al.
Mesenchymal stem cells repress Th17
molecular program through the PD-1 path-
way. PLoS One. 2012; 7: e45272.
58. Luz-Crawford P, Kurte M, Bravo-Alegria J,
et al. Mesenchymal stem cells generate a
CD4+CD25+Foxp3+ regulatory T cell popu-
lation during the differentiation process of
Th1 and Th17 cells. Stem Cell Res Ther.
2013; 4: 65.
59. Fine LG, Norman JT. Chronic hypoxia as a
mechanism of progression of chronic kidney
diseases: from hypothesis to novel thera-
peutics. Kidney Int. 2008; 74: 867–72.
60. Lin SL, Chang FC, Schrimpf C, et al. Target-
ing endothelium-pericyte cross talk by
inhibiting VEGF receptor signaling attenuates
kidney microvascular rarefaction and fibro-
sis. Am J Pathol. 2011; 178: 911–23.
61. Kida Y, Ieronimakis N, Schrimpf C, et al.
EphrinB2 reverse signaling protects against
capillary rarefaction and fibrosis after kid-
ney injury. J Am Soc Nephrol. 2013; 24:
559–72.
62. Humphreys BD, Lin SL, Kobayashi A, et al.
Fate tracing reveals the pericyte and not
epithelial origin of myofibroblasts in kidney
fibrosis. Am J Pathol. 2010; 176: 85–97.
63. Merfeld-Clauss S, Lupov IP, Lu H, et al.
Adipose stromal cell contact with
endothelial cells results in loss of com-
plementary vasculogenic activity mediated
by induction of activin A. Stem Cells.
2015; 33: 3039–51.
64. Merfeld-Clauss S, Gollahalli N, March KL,
et al. Adipose tissue progenitor cells directly
interact with endothelial cells to induce
vascular network formation. Tissue Eng Part
A. 2010; 16: 2953–66.
65. Westenfelder C, Togel FE. Protective
actions of administered mesenchymal stem
cells in acute kidney injury: relevance to clin-
ical trials. Kidney Int Suppl. 2011; 1: 103–6.
1430 ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
